226
Participants
Start Date
May 24, 2016
Primary Completion Date
May 2, 2019
Study Completion Date
May 2, 2019
Ligelizumab
QGE031 240 mg s.c. q4w
Novartis Investigative Site, Taoyuan District
Novartis Investigative Site, Taichung
Novartis Investigative Site, Sydney
Novartis Investigative Site, Campbelltown
Novartis Investigative Site, East Melbourne
Novartis Investigative Site, Woolloongabba
Novartis Investigative Site, Adelaide
Novartis Investigative Site, Taipei
Novartis Investigative Site, Athens
Novartis Investigative Site, Berlin
Novartis Investigative Site, Córdoba
Novartis Investigative Site, Waldorf
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Asheville
Novartis Investigative Site, Alcorcón
Novartis Investigative Site, Málaga
Novartis Investigative Site, Hanover
Novartis Investigative Site, Sarasota
Novartis Investigative Site, Birmingham
Novartis Investigative Site, Seville
Novartis Investigative Site, Owensboro
Novartis Investigative Site, Toledo
Novartis Investigative Site, Cincinnati
Novartis Investigative Site, Valencia
Novartis Investigative Site, Evansville
Novartis Investigative Site, Münster
Novartis Investigative Site, Mainz
Novartis Investigative Site, Rochester
Novartis Investigative Site, St Louis
Novartis Investigative Site, Little Rock
Novartis Investigative Site, Dallas
Novartis Investigative Site, Fort Worth
Novartis Investigative Site, Freiburg im Breisgau
Novartis Investigative Site, Munich
Novartis Investigative Site, Scottsdale
Novartis Investigative Site, Lake Oswego
Novartis Investigative Site, Moscow
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Smolensk
Novartis Investigative Site, Chelyabinsk
Novartis Investigative Site, Providence
Novartis Investigative Site, South Burlington
Novartis Investigative Site, Toronto
Novartis Investigative Site, Waterloo
Novartis Investigative Site, Québec
Novartis Investigative Site, Dresden
Novartis Investigative Site, Athens
Novartis Investigative Site, Athens
Novartis Investigative Site, Obihiro
Novartis Investigative Site, Kobe
Novartis Investigative Site, Yokohama
Novartis Investigative Site, Kamimashi-gun
Novartis Investigative Site, Kyoto
Novartis Investigative Site, Sakai
Novartis Investigative Site, Saitama
Novartis Investigative Site, Machida
Novartis Investigative Site, Ōta-ku
Novartis Investigative Site, Shinagawa Ku
Novartis Investigative Site, Hiroshima
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Alicante
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Yeovil
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY